Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

558.06 -19.83 (-3.43%)
Streaming Delayed Price Updated: 2:28 PM EDT, Jun 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about argenx SE - American Depositary Shares

< Previous 1 2 3 4 Next >
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
From argenx SE
Via GlobeNewswire
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
From argenx SE
Via GlobeNewswire
argenx Announces Results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx to Present at BofA Securities 2025 Health Care Conference
From argenx SE
Via GlobeNewswire
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
From argenx SE
Via GlobeNewswire
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From argenx SE
Via GlobeNewswire
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
From argenx SE
Via GlobeNewswire
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
From argenx SE
Via GlobeNewswire
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
From argenx SE
Via GlobeNewswire
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
argenx to Present at TD Cowen 45th Annual Healthcare Conference
From argenx SE
Via GlobeNewswire
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
From argenx SE
Via GlobeNewswire
argenx Highlights 2025 Strategic Priorities
From argenx SE
Via GlobeNewswire
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
From argenx SE
Via GlobeNewswire
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
From argenx SE
Via GlobeNewswire
argenx to Participate at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
From argenx SE
Via GlobeNewswire
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
From argenx SE
Via GlobeNewswire
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
From argenx SE
Via GlobeNewswire
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.